Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its second quarter 2023 financial results on August 2, 2023. The company will host a conference call to discuss the financial results and other updates at 8:00 a.m. ET on the same day. Investors can access the call and webcast through the company's website or by dialing the provided numbers. This announcement indicates the company's commitment to transparency and communication with its stakeholders, which can positively impact investor confidence and stock performance.

Positive

• The scheduled conference call demonstrates the company's commitment to transparent communication with stakeholders, which can enhance investor confidence and potentially positively impact stock performance.

Negative

• None.

-- Conference Call Scheduled for Wednesday, August 2, 2023, at 8:00 a.m. ET --

NEWTON, Mass., July 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2023 financial results on Wednesday, August 2, 2023. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, August 2, 2023, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2023-financial-results-on-august-2-2023-301885642.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm Therapeutics report its second quarter 2023 financial results?

Karyopharm Therapeutics will report its second quarter 2023 financial results on August 2, 2023.

What time is the conference call to discuss the financial results?

The conference call to discuss the financial results will be at 8:00 a.m. ET on August 2, 2023.

How can I access the conference call and webcast?

Investors can access the conference call and webcast through the company's website or by dialing (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time.